Latest report! Next generation cancer diagnosis market analysis January 10, 2017 Source: Bio-Exploration Recently, GRAND VIEW RESEARCH website released the global next-generation cancer diagnosis market report, analyzing the development trend of the global cancer diagnosis market from 2013 to 2024. According to the report, in 2015, the global market for next-generation cancer diagnosis exceeded $4.38 billion, and it is expected to see significant growth during the forecast period. This report analyzes the development trend of the next-generation cancer diagnosis market in the next few years from the perspectives of technology, application areas, and enterprise layout. Report range 1. Five major factors driving market development The rise in cancer incidence has increased the demand for the next generation of cancer diagnostic testing markets. The development of testing will promote the early diagnosis of cancer and the effective prognosis of various types of cancer, which in turn will have a positive impact on the vertical field of cancer diagnosis. Large enterprises continue to develop and introduce products, which are expected to provide a favorable growth path for the market. As the accompanying diagnosis of personalized medicine or precision medicine accelerates, the next-generation cancer diagnosis market has the potential for high value and huge development space. The active participation of relevant global organizations, such as the National Cancer Institute, the National Cancer Research Foundation and the UK Cancer Institute, has driven the development of the entire market. The further development of diagnostic laboratories and the adoption of integrated automated laboratory systems are expected to increase market demand for advanced workflow systems and boost market revenues during the forecast period. The shift from traditional laboratory testing to rapid on-the-fly testing (POCT) will further expand the market value, thanks to the commercialization of diagnostic kits, instruments and reagents. 2, chip technology usage rate declines, NGS occupies more markets Currently, the key technologies for the next generation of cancer diagnostics market are DNA chips, protein chips, qPCR, NGS, and RRT-PCR chip lab technology (lab-on-a-chip (LOAC) device with Reverse Transcriptase Polymerase Chain Reaction (RT-PCR). ) technology). The detection of gene duplications or deletions, melting curve analysis and recognition of mutations, and the use of qPCR in clinical laboratories make qPCR and multiplexing segment technology a considerable market share. Traditional PCR-based detection methods are also considered to be more cost-effective during the forecast period, which is also key to driving this segment of market value growth. In recent years, with the development of NGS systems and library preparation and data interpretation tools, NGS technology has become more and more popular among research units, and the market's preference for it has gradually increased. The report predicts that the use of DNA and protein chip technology will decline during the forecast period, and NGS technology will increasingly be used in the market. Other market analysis reports also mentioned that DNA chips are expected to lose important market share, and NGS-based diagnostics will account for more and more markets in the next decade. 3. The market for biomarkers, genetic analysis and prognosis will grow substantially Based on the fact that the detection accuracy of biomarkers in research can reach 90%, the application of biomarkers improves the sensitivity of tumor screening. The report predicts that market demand for biomarkers will increase significantly in the coming years. With more and more related projects and tools to promote early detection of tumors, the market for cancer genetic analysis will expand in the next few years. The next-generation cancer diagnosis market can be broadly classified into areas such as risk analysis, tumor screening, diagnosis-based prognosis, treatment monitoring, and concomitant diagnosis. Because the prognosis of patients with different cancers is different, and the prognosis plays a crucial role in personalized therapy, chemotherapy, radiation therapy and gene therapy, the prognosis diagnosis market will increase significantly during the forecast period. 4, lung cancer, breast cancer market growth space According to the development of tumors, the next-generation cancer diagnosis market can be divided into breast cancer, cervical cancer, colorectal cancer, lung cancer and other cancers. Other common types of cancer include leukemia, bladder cancer, brain cancer, skin cancer, uterine cancer, non-Hodgkin's lymphoma, esophageal cancer, liver cancer, ovarian cancer, prostate cancer, and thyroid cancer. In terms of market value, lung cancer was classified as the second largest category of cancer in 2015 because of the relatively large number of research projects and patent applications related to it. In addition, lung cancer is the most prevalent cancer worldwide, requiring a larger market to meet the needs of large patients. The report predicts that breast cancer market value will increase significantly in the next few years. The rising incidence of breast cancer increases the market demand for diagnostic and screening technologies. 5. Targeting a large number of undeveloped Asia Pacific markets From the perspective of global zoning, the next-generation tumor diagnosis industry market is dominated by North America, which accounts for more than 40% of the market. The report pointed out that the government's favorable measures, such as "80% of colorectal cancer testing by 2018" are expected to promote market growth. 170 government agencies, including the government health department, the medical professional group, and the Cancer Alliance, are participating in the project. They strive to achieve 80% of cancer screening by 2018 and promise to eradicate the tumor. The market value in the Asia Pacific region is expected to grow the fastest as there are a large number of untapped markets in the region, and in recent years the Asia Pacific region has made significant progress in healthcare research. In addition, the investment in health care in the Asia-Pacific region has greatly increased in recent years, and it is expected to further promote market growth. 6. Enterprises actively expand insurance strategy Currently, the world's next-generation tumor diagnostics market is dominated by: Cepheid, Koninklijke Philips NV, F. Hoffmann-La Roche Ltd, Qiagen, Novartis AG, Abbott, Thermo Fisher Scientific, Inc., Opko Health, Inc., Myriad Genetics, Inc., Agilent Technologies, GE Healthcare, PerkinElmer, Inc., Genomic Health, Inc., Illumina, Inc., Hologic, Inc., Almac Group, Janssen Global Services, LLC, and Sysmex Corporation, and the like. Companies expand their marketing strategies by providing clinical trial facilities in undeveloped areas. At present, more and more companies are actively expanding the coverage of insurance reimbursement to improve the accessibility of patients to precision medicine. For example, in October 2015, the United States launched the Oncotype Dx reimbursement process (mainly for prostate cancer testing) to reduce the burden on patients. Independence Blue Cross and NantHealth, a healthcare organization in 2016, announced that GPS Cancer TM, a comprehensive molecular diagnostics platform based on genome-wide and proteomic, has become the nation's first insurance-reimbursed clinical cancer test. Fruit and vegetable powder is the fresh fruits and vegetables through the international advanced level of freeze-drying technology and equipment, after pretreatment, quick-freezing, vacuum drying, ultraviolet sterilization, packaging storage and other more than 10 processes. Fruit And Vegetable Powder ,Wheat Straw Juice Powder ,Alfalfa Juice Powder,Celery Juice Powder Xi'an Double H Health Technology Co., Ltd , https://www.dhextract.com